Exeo Group Inc. logo

Exeo Group Inc. (1951)

Market Closed
10 Aug, 06:00
JPX JPX
¥
2,581. 00
-95
-3.5501%
¥
- Market Cap
- P/E Ratio
0.01% Div Yield
1.4M Volume
- Eps
¥ 2,676
Previous Close
Add Transaction
Day Range
2,569 2,648
Year Range
2,087 3,058
Want to track 1951 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1951 closed yesterday lower at ¥2,581, a decrease of -3.5501% from Friday's close, completing a monthly decrease of -7.491% or -¥209. Over the past 12 months, 1951 stock lost -1.3002%.
1951 pays dividends to its shareholders, with the most recent payment made on Dec 01, 2025. The next announced payment will be in In 1 month on Sep 29, 2026 for a total of ¥40.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Exeo Group Inc. has completed 1 stock splits, with the recent split occurring on Mar 28, 2024.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

1951 Chart

Exeo Group Inc. (1951) FAQ

What is the stock price today?

The current price is ¥2,581.00.

On which exchange is it traded?

Exeo Group Inc. is listed on JPX.

What is its stock symbol?

The ticker symbol is 1951.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.01%.

What is its market cap?

As of today, no market cap data is available.

Has Exeo Group Inc. ever had a stock split?

Exeo Group Inc. had 1 splits and the recent split was on Mar 28, 2024.

Exeo Group Inc. Profile

Health Care Providers & Services Industry
Healthcare Sector
Mr. Yang Dong CEO
JPX Exchange
JP3254200003 ISIN
DE Country
3,365 Employees
29 Jun 2026 Last Dividend
- Last Split
- IPO Date

Overview

Jinxin Fertility Group Limited operates as an investment holding company specializing in providing a comprehensive range of assisted reproductive services (ARS) across China and the United States. Established in 1951 and based in Chengdu, China, the company has expanded its offerings beyond basic fertility treatments to include a wide array of related healthcare and ancillary services. These offerings range from nutritional guidance and Chinese medicine treatments to obstetrics, gynecology, and even property investment along with other healthcare-related services. Catering to the diverse needs of its clients, Jinxin Fertility Group Limited employs state-of-the-art technologies and methodologies in its treatment solutions, making it a significant player in the ARS industry.

Products and Services

The products and services offered by Jinxin Fertility Group Limited reflect its dedication to providing end-to-end solutions in the field of reproductive health and wellness. These include:

  • Artificial Insemination: This service is performed using either the husband's sperm or donor sperm, catering to a variety of family planning scenarios.
  • IVF Technology: The company employs conventional in vitro fertilization and embryo transfer techniques, as well as IVF with intracytoplasmic sperm injection, to maximize the chances of successful pregnancy.
  • Related Services: To complement its ARS, Jinxin Fertility Group offers nutrition guidance, Chinese medicine treatment, and psychological counseling, aiming to support the overall well-being of its clients during their fertility journey.
  • Medical and Surgical Services: The company's healthcare services extend to obstetrics, gynecology, urology, internal medicine, and pediatrics, along with providing access to ambulatory surgery center facilities.
  • Ancillary Medical Services: These include pre-implantation genetic screening, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital-derived services, ensuring comprehensive care before, during, and after pregnancy.
  • Property Investment and Real Estate: Beyond healthcare, Jinxin Fertility Group is involved in property investment, real estate development, and operation activities, showcasing its diverse business interests.
  • Sale of Medicines, Consumables, and Equipment: The company provides a range of healthcare products, which are essential for the delivery of its ARS and medical services.
  • Research and Development: Jinxin is committed to the advancement of IVF technologies and projects, focusing on scientific research and the commercialization of these innovations.
  • Restaurant Operation: An outlier among its offerings, the company also manages a restaurant, reflecting its diverse portfolio of investments and services.

Contact Information

Address: No. 301, North Jingsha Road, Chengdu, China
Phone: 86 28 6769 5992